The association of early toxicity and outcomes for patients treated with abemaciclib.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.1053
Abstract: 1053Background: Abemaciclib is a CDK4 & 6 inhibitor dosed on a continuous schedule and has demonstrated efficacy with an acceptable safety profile in patients (pts) with hormone receptor-positive, ... read more here.
Keywords: toxicity outcomes; patients treated; outcomes patients; treated abemaciclib ... See more keywords